IP Library Granted Patent US 12,071,649
Granted Patent B1
US 12,071,649 · App. 16/207,796 · Granted Aug 27, 2024

Identification of modulators of nitration and therapeutic uses thereof

Inventors: Irene Griswold-Prenner (Jackson, WY); Sami Hussain (San Francisco, CA); Vu Cao Dang (San Mateo, CA)
Assignee: Nitrase Therapeutics, Inc.
C12Q1/25C07K16/18G01N33/6896G01N2440/00G01N2500/20G01N2800/2835
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,071,649
App. No.
16/207,796
Granted
Aug 27, 2024
Kind
B1
Abstract

The present invention features methods for identifying treatments for neurodegenerative diseases, e.g., Parkinson's disease. Described are purification methods for synuclein nitration enzyme and screening methods for identifying agents that inhibit synuclein nitration enzyme activity.

Claims (15)

1. A method of identifying a compound that inhibits a nitration enzyme, said method comprising:

(a) providing a first composition comprising an α-synuclein, peroxynitrite, and the nitration enzyme;

(b) providing a second composition by contacting a compound with said first composition; and

(c) measuring the level of nitrated α-synuclein in the second composition, wherein a reduction in the level of nitrated α-synuclein in the second composition compared to the first composition indicates that the compound inhibits the nitration enzyme, and wherein the nitration enzyme is an α-synuclein nitration enzyme.

2. The method of claim 1 , wherein the α-synuclein contains tyrosine nitrated by synuclein nitrase or any one of SEQ ID NOS: 1-4.

3. The method of claim 1 , wherein measuring the level of nitrated α-synuclein comprises:

(i) contacting the second composition with a nitrated α-synuclein antibody or a nitrotyrosine antibody; and

(ii) measuring the optical density of the level of nitrated α-synuclein.

4. The method of claim 1 , wherein said compound comprises a nitromethane moiety.

5. The method of claim 1 , wherein said compound comprises a peroxynitrite moiety.

6. A method of inhibiting α-synuclein nitration enzyme in a subject in need thereof, said method comprising administering to the subject a compound identified using the method of claim 1 .

7. The method of claim 6 , wherein the subject in need thereof suffers from a neurodegenerative disease.

8. The method of claim 7 , wherein the neurodegenerative disease comprises Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, or Huntington's disease.

9. The method of claim 6 , wherein the compound comprises a peroxynitrite moiety.

10. The method of claim 6 , wherein the compound comprises a nitromethane moiety.

Assignments (2)
CHANGE OF NAME Recorded Jan 31, 2022
From: NITROME BIOSCIENCES, INC.
To: NITRASE THERAPEUTICS, INC.
Reel/Frame 058905/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: GRISWOLD-PRENNER, IRENE; HUSSAIN, SAMI; DANG, VU CAO
To: NITROME BIOSCIENCES, INC.
Reel/Frame 047901/0688 →
Continuity (1)
Provisional Application 62593941 · Dec 3, 2017